	Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
	Gilead Eyes HIV Market Domination With Twice-Yearly Yeztugo as GSK Trails
	Gilead’s HIV Breakthrough
	Gilead’s Yeztugo HIV Shot Poised For Wider Reach After SCOTUS Ruling On Preventive Coverage: Wells Fargo
	SCOTUS ruling paves smooth launch path for Gilead's long-acting PrEP med Yeztugo, analyst says
	Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials
	Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer